Suven Life Sciences surges on securing three product patents in Israel, Macau and USA

16 Jun 2015 Evaluate

Suven Life Sciences is currently trading at Rs. 245.50, up by 2.50 points or 1.03% from its previous closing of Rs. 243.00 on the BSE.

The scrip opened at Rs. 243.50 and has touched a high and low of Rs. 252.80 and Rs. 238.25 respectively. So far 41026 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 85.25 on 16-Jun-2014.

Last one week high and low of the scrip stood at Rs. 252.80 and Rs. 225.00 respectively. The current market cap of the company is Rs. 3036.96 crore.

The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 8.36% and 32.20% respectively.

Suven Life Sciences has secured three product patents. Of total, the company has received one product patent from Israel (198821), Macau (J/001515) and USA (9018231) each corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, the company has a total of five granted patents from Israel, four granted patents from Macau and twenty one granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

 

Suven Life Sciences Share Price

171.60 -5.75 (-3.24%)
16-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2085.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×